126 related articles for article (PubMed ID: 21996443)
1. Crystal structure of the LG3 domain of endorepellin, an angiogenesis inhibitor.
Le BV; Kim H; Choi J; Kim JH; Hahn MJ; Lee C; Kim KK; Hwang HY
J Mol Biol; 2011 Nov; 414(2):231-42. PubMed ID: 21996443
[TBL] [Abstract][Full Text] [Related]
2. Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells.
Willis CD; Poluzzi C; Mongiat M; Iozzo RV
FEBS J; 2013 May; 280(10):2271-84. PubMed ID: 23374253
[TBL] [Abstract][Full Text] [Related]
3. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan.
Gonzalez EM; Reed CC; Bix G; Fu J; Zhang Y; Gopalakrishnan B; Greenspan DS; Iozzo RV
J Biol Chem; 2005 Feb; 280(8):7080-7. PubMed ID: 15591058
[TBL] [Abstract][Full Text] [Related]
4. Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.
Goyal A; Pal N; Concannon M; Paul M; Doran M; Poluzzi C; Sekiguchi K; Whitelock JM; Neill T; Iozzo RV
J Biol Chem; 2011 Jul; 286(29):25947-62. PubMed ID: 21596751
[TBL] [Abstract][Full Text] [Related]
5. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan.
Mongiat M; Sweeney SM; San Antonio JD; Fu J; Iozzo RV
J Biol Chem; 2003 Feb; 278(6):4238-49. PubMed ID: 12435733
[TBL] [Abstract][Full Text] [Related]
6. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin.
Bix G; Fu J; Gonzalez EM; Macro L; Barker A; Campbell S; Zutter MM; Santoro SA; Kim JK; Höök M; Reed CC; Iozzo RV
J Cell Biol; 2004 Jul; 166(1):97-109. PubMed ID: 15240572
[TBL] [Abstract][Full Text] [Related]
7. Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing.
Jung M; Lord MS; Cheng B; Lyons JG; Alkhouri H; Hughes JM; McCarthy SJ; Iozzo RV; Whitelock JM
J Biol Chem; 2013 Feb; 288(5):3289-304. PubMed ID: 23235151
[TBL] [Abstract][Full Text] [Related]
8. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity.
Woodall BP; Nyström A; Iozzo RA; Eble JA; Niland S; Krieg T; Eckes B; Pozzi A; Iozzo RV
J Biol Chem; 2008 Jan; 283(4):2335-43. PubMed ID: 18024432
[TBL] [Abstract][Full Text] [Related]
9. Endorepellin evokes autophagy in endothelial cells.
Poluzzi C; Casulli J; Goyal A; Mercer TJ; Neill T; Iozzo RV
J Biol Chem; 2014 Jun; 289(23):16114-28. PubMed ID: 24737315
[TBL] [Abstract][Full Text] [Related]
10. Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor.
Bix G; Iozzo RA; Woodall B; Burrows M; McQuillan A; Campbell S; Fields GB; Iozzo RV
Blood; 2007 May; 109(9):3745-8. PubMed ID: 17197432
[TBL] [Abstract][Full Text] [Related]
11. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism.
Bix G; Castello R; Burrows M; Zoeller JJ; Weech M; Iozzo RA; Cardi C; Thakur ML; Barker CA; Camphausen K; Iozzo RV
J Natl Cancer Inst; 2006 Nov; 98(22):1634-46. PubMed ID: 17105986
[TBL] [Abstract][Full Text] [Related]
12. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity.
Nyström A; Shaik ZP; Gullberg D; Krieg T; Eckes B; Zent R; Pozzi A; Iozzo RV
Blood; 2009 Nov; 114(23):4897-906. PubMed ID: 19789387
[TBL] [Abstract][Full Text] [Related]
13. Endorepellin-evoked Autophagy Contributes to Angiostasis.
Goyal A; Gubbiotti MA; Chery DR; Han L; Iozzo RV
J Biol Chem; 2016 Sep; 291(37):19245-56. PubMed ID: 27435676
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V.
Friedrich MV; Göhring W; Mörgelin M; Brancaccio A; David G; Timpl R
J Mol Biol; 1999 Nov; 294(1):259-70. PubMed ID: 10556044
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the high-affinity interaction of nidogen-1 with immunoglobulin-like domain 3 of perlecan.
Kvansakul M; Hopf M; Ries A; Timpl R; Hohenester E
EMBO J; 2001 Oct; 20(19):5342-6. PubMed ID: 11574465
[TBL] [Abstract][Full Text] [Related]
16. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
[TBL] [Abstract][Full Text] [Related]
17. A fragment of the LG3 peptide of endorepellin is present in the urine of physically active mining workers: a potential marker of physical activity.
Parker TJ; Sampson DL; Broszczak D; Chng YL; Carter SL; Leavesley DI; Parker AW; Upton Z
PLoS One; 2012; 7(3):e33714. PubMed ID: 22457785
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure and mutational analysis of a perlecan-binding fragment of nidogen-1.
Hopf M; Göhring W; Ries A; Timpl R; Hohenester E
Nat Struct Biol; 2001 Jul; 8(7):634-40. PubMed ID: 11427896
[TBL] [Abstract][Full Text] [Related]
19. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis.
Cailhier JF; Sirois I; Laplante P; Lepage S; Raymond MA; Brassard N; Prat A; Iozzo RV; Pshezhetsky AV; Hébert MJ
J Biol Chem; 2008 Oct; 283(40):27220-9. PubMed ID: 18658137
[TBL] [Abstract][Full Text] [Related]
20. Identification of circulating endorepellin LG3 fragment: Potential use as a serological biomarker for breast cancer.
Chang JW; Kang UB; Kim DH; Yi JK; Lee JW; Noh DY; Lee C; Yu MH
Proteomics Clin Appl; 2008 Jan; 2(1):23-32. PubMed ID: 21136776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
